Trial · NCT02960893
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Randomization Phase (8 Weeks) | STARTED | Troriluzole - Randomization Phase | 71 | |
| Randomization Phase (8 Weeks) | STARTED | Placebo - Randomization Phase | 70 | |
| Randomization Phase (8 Weeks) | STARTED | Troriluzole/Troriluzole - Open Label Extension (OLE) Phase | 0 | |
| Randomization Phase (8 Weeks) | STARTED | Placebo/Troriluzole - OLE Phase | 0 | |
| Randomization Phase (8 Weeks) | COMPLETED | Troriluzole - Randomization Phase | 64 | |
| Randomization Phase (8 Weeks) | COMPLETED | Placebo - Randomization Phase | 68 | |
| Randomization Phase (8 Weeks) | COMPLETED | Troriluzole/Troriluzole - Open Label Extension (OLE) Phase | 0 | |
| Randomization Phase (8 Weeks) | COMPLETED | Placebo/Troriluzole - OLE Phase | 0 | |
| Randomization Phase (8 Weeks) | NOT COMPLETED | Troriluzole - Randomization Phase | 7 | |
| Randomization Phase (8 Weeks) | NOT COMPLETED | Placebo - Randomization Phase | 2 | |
| Randomization Phase (8 Weeks) | NOT COMPLETED | Troriluzole/Troriluzole - Open Label Extension (OLE) Phase | 0 | |
| Randomization Phase (8 Weeks) | NOT COMPLETED | Placebo/Troriluzole - OLE Phase | 0 | |
| Open Label Extension Phase (336 Weeks) | STARTED | Troriluzole - Randomization Phase | 0 | |
| Open Label Extension Phase (336 Weeks) | STARTED | Placebo - Randomization Phase | 0 | |
| Open Label Extension Phase (336 Weeks) | STARTED | Troriluzole/Troriluzole - Open Label Extension (OLE) Phase | 64 | |
| Open Label Extension Phase (336 Weeks) | STARTED | Placebo/Troriluzole - OLE Phase | 67 | |
| Open Label Extension Phase (336 Weeks) | COMPLETED | Troriluzole - Randomization Phase | 0 | |
| Open Label Extension Phase (336 Weeks) | COMPLETED | Placebo - Randomization Phase | 0 | |
| Open Label Extension Phase (336 Weeks) | COMPLETED | Troriluzole/Troriluzole - Open Label Extension (OLE) Phase | 28 | |
| Open Label Extension Phase (336 Weeks) | COMPLETED | Placebo/Troriluzole - OLE Phase | 36 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02960893/flow